Hot Features
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosph... Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.000299999999999 | -0.00424929178469 | 7.06 | 8.02 | 6.91 | 724887 | 7.38309278 | CS |
| 4 | -0.8803 | -11.0869017632 | 7.94 | 8.74 | 6.89 | 691899 | 7.6188306 | CS |
| 12 | 0.0097 | 0.137588652482 | 7.05 | 8.74 | 6.045 | 583112 | 7.29819538 | CS |
| 26 | 0.4897 | 7.45357686454 | 6.57 | 8.74 | 5.35 | 539823 | 6.86449385 | CS |
| 52 | 6.2597 | 782.4625 | 0.8 | 8.74 | 0.47 | 1002208 | 3.45042527 | CS |
| 156 | 5.6897 | 415.306569343 | 1.37 | 8.74 | 0.202 | 934957 | 1.60781142 | CS |
| 260 | -1.4903 | -17.4304093567 | 8.55 | 8.74 | 0.202 | 1039522 | 1.73385548 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.